Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Endometrial Adenocarcinoma 1

Interventions

Specimen Handling 39Magnetic Resonance Spectroscopy 33Cyclophosphamide 30Doxorubicin 24Biopsy 24pembrolizumab 22Temozolomide 22Radiotherapy 20Radiation 19X-Rays 18Nivolumab 15Vincristine 13Irinotecan 13fludarabine 12Phantoms, Imaging 12Ifosfamide 12Gemcitabine 12atezolizumab 11cabozantinib 10Ipilimumab 9Bevacizumab 9liposomal doxorubicin 8Surgical Procedures, Operative 8Paclitaxel 8Immunoglobulin G 8Etoposide 8Dactinomycin 7Carboplatin 7palbociclib 6olaparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epothilones × Sarcoma × 90 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡